Conditions: Non-Hodgkins Lymphoma
Keywords: celgene cc-5013 CC5013 NHL Non-Hodgkins Lymphoma Revlimid
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 50
Healthy volunteers: no

Brief summary:
To determine the activity of lenalidomide in relapsed or refractory aggressive NHL.

Detailed description:

Arms:
arm 1: Participants received single-agent lenalidomide 25 mg orally once daily on Days 1 to 21 of every 28-day cycle for up to 52 weeks or until disease progression developed, lenalidomide treatment was discontinued for any reason, or the study was terminated.

Interventions: intervention 1: Lenalidomide
Intervention descriptions: intervention 1: Capsules for oral administration.

Protocol document: